地夸磷索钠联合强脉冲光治疗睑板腺功能障碍

Diquafosol sodium combined with intense pulsed light in the treatment of meibomian gland dysfunction

摘要:

目的：探讨3%地夸磷索钠滴眼液联合强脉冲光治疗睑板腺功能障碍的疗效及睑板腺形态的变化。

方法：前瞻性研究。选取2021-01/2022-05在我院确诊的睑板腺功能障碍患者141例282眼，使用数字表法随机分为对照组(73例146眼，给予0.3%玻璃酸钠滴眼液联合强脉冲光治疗)及观察组(68例136眼，给予3%地夸磷索钠滴眼液联合强脉冲光治疗)。结束治疗后2wk对两组主观症状评分、体征评分、非侵入性泪膜破裂时间、泪河高度、泪膜脂质层厚度、睑板腺密度情况等进行比较及两组治疗前后的差异性。

结果：两组患者治疗前主观症状评分、体征评分、非侵入性泪膜破裂时间、泪河高度、泪膜脂质层厚度、睑板腺密度等比较均无差异(P>0.05)。治疗后2wk两组患者眼部症状评分、体征评分均持续降低，非侵入性泪膜破裂时间、泪膜脂质层厚度均持续升高，睑板腺密度均增加，观察组泪河高度升高而对照组变化不明显。观察组各项临床指标均优于对照组(P<0.05)。所有患者均未见明显并发症发生。

结论：地夸磷索钠联合强脉冲光在睑板腺功能障碍治疗中相互协同，疗效显著且能促进睑板腺修复，明显优于单纯强脉冲光治疗。

Abstract:

AIM:To investigate the effect of 3% diquafosol sodium eye drops combined with intense pulsed light on the treatment of meibomian gland dysfunction and the change of meibomian glands.

METHODS: Prospective study. A total of 141 patients(282 eyes)who were diagnosed with meibomian gland dysfunction from January 2021 to May 2022 in our hospital were selected and they were randomly divided into the control group(73 cases, 146 eyes)and the observation group(68 cases, 136 eyes)according to random number table. The control group was given 0.3% sodium hyaluronate eye drops combined with intense pulsed light, and the observation group was treated with 3% diquafosol sodium eye drops combined with intense pulsed light. The subjective symptom score, physical sign score, non-invasive tear break-up time, tear meniscus height, lipid layer thickness, and meibomian gland density before and after the treatment were compared between the two groups at 2wk after the end of treatment.

RESULTS: There were no differences in the subjective symptom score, physical sign score, non-invasive tear break-up time, tear meniscus height, lipid layer thickness, and meibomian gland density between the two groups of patients before treatment(P>0.05). After 2wk of treatment, the symptom scores and physical sign scores of patients in the two groups continued to decrease, non-invasive tear break-up time and lipid layer thickness continued to increase, and the meibomian gland density also increased. The tear meniscus height in the observation group increased, while the control group showed no significant changes. The observation group had better clinical indicators than the control group(P<0.05). No obvious complications were observed in all patients.

CONCLUSION: The combination of diquafosol sodium eye drops and intense pulsed light is synergistic in the treatment of meibomian gland dysfunction, with significant therapeutic effects and improvement of meibomian gland repair, which is significantly superior to simple intense pulsed light therapy.